Background: The purpose of this study was to determine the clinical activity of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.
introduction Prostate cancer is a major cause of cancer morbidity and mortality. After failure of hormone therapy, a disease state termed as castration-resistant prostate cancer (CRPC); the standard chemotherapy for patients with metastatic disease is docetaxel [1, 2] . Treatment with docetaxel improves median overall survival in patients with CRPC by 3 months and is associated with a median time to progression of 6 months. In addition, 40%-50% of patients experience a prostate-specific antigen (PSA) decline of ‡50% from baseline and 30% a reduction in pain with docetaxel. The optimal treatment strategy for patients who progress during or after treatment with docetaxel continues to be defined. Patupilone (epothilone B, EPO906) is an epothilone and novel beta-tubulin-targeting agent, which is active across a broad range of taxane-sensitive and taxane-resistant cell lines including those derived from human prostate cancer [3] . In phase I studies with patupilone on weekly and every 3-week administration schedules, antitumor activity was observed with dose-limiting toxicity chiefly comprising of diarrhea [4, 5] . There was minimal hematologic toxicity, which is advantageous when considering treatment of a population of men that frequently have compromised bone marrow function from involvement with metastatic cancer and pretreated with chemotherapy and radiation therapy. A phase II study with weekly administration of patupilone in a mixed population of chemotherapy-naive and chemotherapy-pretreated patients demonstrated a modest rate of activity with 13% of patients experiencing a ‡50% PSA decline from baseline [6] . With preclinical evidence suggesting an improved therapeutic index with single higher dosing as opposed to more frequent administration at lower doses, this phase II study was undertaken to evaluate patupilone in a 3-weekly schedule in patients with CRPC who had previously received docetaxel.
patients and methods

eligibility criteria
To be eligible, patients had to have a pathologic diagnosis of adenocarcinoma of the prostate with evidence of metastatic disease and castration resistance [7] , a serum PSA of ‡ 5 lg/l, and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of less than or equal to two. Patients must have had evidence of progression while receiving or within 6 months after the completion of docetaxel-based chemotherapy. Progression was defined as either rising PSA [an increase in PSA of 25% (minimum 5 ng/ml) above baseline value, confirmed by a second PSA of increasing value at least 1 week later; in patients who had experienced a confirmed PSA decline of ‡50% from baseline, progression was considered to have occurred with a confirmed rise in PSA of 50% (minimum 5 ng/ml) above nadir value] or measurable disease progression as per RECIST or cancer-related symptomatic progression (new or worsening disease symptoms requiring palliative radiotherapy or change in antineoplastic therapy or disease-related fall in ECOG PS by ‡2 levels).
Patients were required to maintain medical castration therapy. Prior radiation was permitted provided a minimum of 4 weeks had elapsed before enrollment. Patients had to have adequate function of the bone marrow (neutrophils ‡ 1.5 · 10 9 /l, platelets ‡ 100 · 10 9 /l, hemoglobin ‡ 90 g/l), liver [bilirubin £ 1.0 · upper limit of normal (ULN), aspartate aminotransferase/alanine aminotransferase £ 2.5 · ULN], and kidney (serum creatinine £ 1.5 · ULN). Patients were not eligible if they had received prior strontium and had a history of previous invasive cancer, brain metastases, other serious medical illness, peripheral neuropathy >grade 1 (Common Terminology Criteria for Adverse Events Version 3.0), ‡1 grade diarrhea, or ongoing anticoagulation with warfarin. All patients provided written informed consent. The study was registered (ClinicalTrials.gov identifier: NCT00407251) and approved by the institutional review boards of participating centers.
treatment plan and evaluations
Protocol treatment was to begin within 3 days of enrollment. Patupilone (provided by Novartis Pharmaceuticals, Basel, Switzerland) was initially delivered at a starting dose of 10 mg/m 2 i.v. over 20 min repeated every 3
weeks. Due to concerns of a high rate of gastrointestinal adverse events in the first six patients, the starting dose was decreased to 8 mg/m2 for all subsequent patients. In the case of grade 3 toxicity, doses were held until recovery (maximum 2 weeks) then reduced by 2 mg/m 2 . Patients experiencing grade 3 peripheral neuropathy were discontinued from protocol therapy. Doses were held then reduced for grade 2 diarrhea persisting for >14 days and for grade 3 diarrhea lasting longer than 3 days or grade 4 diarrhea <24 h despite maximal medical therapy. Patients with grade 4 diarrhea lasting >24 h were removed from protocol therapy. Patients experiencing other grade 4 toxicity discontinued protocol therapy. Otherwise, treatment was continued until RECIST-defined disease progression [8] or cancer-related symptomatic progression (new or worsening disease symptoms requiring palliative radiotherapy or change in systemic therapy or disease-related fall in ECOG PS by ‡2 levels). Patients could continue therapy with rising PSA in the absence of other indicators of disease progression. At baseline, all patients underwent a complete history and physical exam, laboratory blood tests and radiological imaging consisting of chest X-ray or computed tomography (CT) scan, bone scan, and abdominal/pelvic CT scan. Laboratory blood tests for hematology, biochemistry, and PSA were repeated day 1 of every cycle. Radiological imaging of measurable disease and bone scans were repeated every 12 weeks. Increasing lesions on bone scans that were asymptomatic were not considered as progression.
outcome measures
All patients were considered assessable for toxicity from the time of their first treatment. Response and progression were evaluated by RECIST. All patients who had received at least one cycle of therapy and who had two or more PSA measurements at least 3 weeks apart following baseline were considered assessable for PSA decline assessment. The primary end point of this study was the proportion of patients experiencing a PSA decline of ‡50% maintained for ‡3 weeks without other evidence of disease progression. PSA progression was defined as a rise in PSA of 25% (minimum 5 ng/ml) above baseline value, confirmed by a second PSA of increasing value at least 1 week later. In patients who had experienced a confirmed PSA decline of ‡50% from baseline, progression was considered to have occurred with a confirmed rise in PSA of 50% (minimum 5 ng/ml) above nadir value. Progression-free survival (PFS) was defined as time from first treatment to the time of progression as defined above or time of death if patients had not progressed. Overall survival was calculated from the date of first treatment until death from any cause. Patient-reported present pain intensity was determined using a weekly self-administered six-point scale (0 = no pain, 5 = excruciating pain) [9] . A pain response was defined as any decrease by two points or from 1 to 0 if baseline pain score was 1. Weekly narcotic analgesic use was averaged per cycle. An analgesic use 'response' was considered as a 50% decrease from baseline, while progression was defined as a 25% increase in analgesic use maintained for at least 3 weeks [9] .
statistical considerations
It was hypothesized that patupilone would be considered of interest if 25% or more of patients had a ‡50% PSA decline and of no interest if the proportion was £15%. A two-stage Minimax design was used with an alpha level of 0.1 and power of 0.8 with a planned 43 assessable subjects to be accrued during stage I and 28 during stage II. If six or fewer responses were observed during the first stage, then accrual to the trial was to be stopped. If 14 or fewer responses were observed by the end of the trial, then no further investigation of the drug for this indication was considered warranted. PFS and overall survival were estimated by the method of Kaplan-Meier. Table 1 . The median time to progression after the last docetaxel of 1.4 months, 52% of patients had received two or more prior chemotherapy regimens, and 20% of patients had not experienced a PSA decline with prior docetaxel. Median duration of prior docetaxel therapy was 28 weeks.
treatments administered
A total of 559 cycles of therapy were delivered with a median of 6 cycles (range 1-21) administered per patient. For the 77 patients who had a starting dose of 8 mg/m 2 , 71% received at least 90% of the planned dose. Twenty-four patients (31%) required a dose reduction and 23 (30%) required a dose delay for adverse events. Therapy was discontinued for the following reasons: pain progression (1 patient), death (5 patients
adverse events
The first six patients were treated with a starting dose of patupilone of 10 mg/m 2 and four of these six patients developed grade 3 gastrointestinal toxicity (three patients with diarrhea, one patient with ileus). All subsequently enrolled patients were treated with a starting dose of patupilone of 8 mg/m 2 . Commonly reported adverse events that were considered possibly, probably, or definitely related to patupilone at this dose are listed in Table 2 . Diarrhea was the most common adverse event occurring in 85% of patients and was grade ‡3 in 22% of patients. Diarrhea onset occurred at a median of 10 days (range 0-126) after patupilone administration and lasted a median of 7.5 days (1-272). Fatigue and anorexia were also common occurring in 64% (grade ‡3 in 21%) and 45% (grade ‡3 in 10%) of patients, respectively. Hematologic toxicity was minimal, with no significant leucopenia, neutropenia, or thrombocytopenia and only one patient developing grade ‡3 anemia. Preexisting grade 1 sensory neuropathy at baseline was present in 34 (41%) patients. On study, grade 2 neuropathy occurred in 14 patients (17%) and grade 3 and 4 neuropathy occurred in five and two patients, respectively. Adverse events leading to discontinuation of therapy were sensory neuropathy in 11 patients, fatigue in 2 patients, and in 1 patient each: anorexia, parasthesia, diarrhea, thrombocytopenia, elevated creatinine, and pain.
PSA declines
Seventy-nine patients were assessable for PSA declines. A PSA decline of ‡30% and ‡50% from baseline occurred in 46 (58%) and 37 (47%) patients, respectively. A confirmed PSA decline of ‡50% occurred in 30 patients (38%). Forty-two patients had previously progressed while receiving or within 6 weeks after prior docetaxel chemotherapy. In these patients, 21 (50%) and 17 (40%) patients had a PSA decline of ‡30% and ‡50% from baseline, respectively. A waterfall plot of maximal PSA declines per patient is shown in Figure 1 
patient-reported pain scores and analgesic use
Seventy-five patients had recorded baseline pain scores: 13 had a baseline pain score of 0 ('no pain'), 29 a score of 1 ('mild pain'), and 33 a score of 2 or 3 ('discomforting' or 'distressing' pain). Fifty-nine patients with a pain score of ‡1 at baseline were assessable for pain response. Thirty-five patients (59%) had a pain response as defined by a decrease in the present pain intensity score by two points (16 of 32 patients) or from 1 to 0 if baseline pain score was 1 (19 of 27 patients). Twenty four (69%) and 20 (57%) of the 35 patients with the pain response also had a PSA decline of ‡30% and ‡50%, respectively. In the 24 patients without a pain response, 6 (25%) and 5 (21%) had a PSA decline of ‡30% and ‡50%, respectively. Thirty patients were on narcotic analgesics at baseline and assessable for response. Of these patients, 10 (33%) had an analgesic response, 8 of whom were confirmed as lasting >3 weeks (27%). Fifteen patients had stable narcotic analgesic usage and 5 required an increase.
survival
The median time to treatment failure (defined as either progression by RECIST or symptomatic progression) was 4.6 months (95% CI 4.1-6.2). Median overall survival was 11.3 months (95% CI 9.8-15.4). 
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In this phase II multicenter study, treatment with patupilone was active in patients who were progressing after previous docetaxel therapy. Patupilone treatment was associated with a high proportion of patients experiencing PSA declines with 47% of patients having a decline of ‡50%, a partial measurable disease response rate of 24%, a pain response rate of 59%, a decrease in narcotic analgesic use in 33% of patients, and median times to PSA progression and treatment failure of 6.1 and 4.6 months, respectively. This study enrolled patients that were advanced, as indicated by the >50% of patients having two or more previous chemotherapy regimens, experiencing pain at baseline, and/or had progressed while receiving or within 6 weeks of prior docetaxel therapy. The most significant toxicity was diarrhea, although this could be controlled with standard measures [10] . Neuropathy was also common but reflected preexisting neuropathy with patients uncommonly worsening to grade 3 or severity. However, notably absent was significant myelosuppression particularly neutropenia and its complications, which can be problematic in an older and pretreated population of patients with bone metastases.
A frequent treatment maneuver for patients who have previously responded to docetaxel is to retreat with another course of docetaxel and studies of varying methodology have described PSA response rates in the 40%-50% range but the clinical benefit of this strategy has not been defined [11, 12] . Interpretation of studies utilizing tubulin-targeting agents in the postdocetaxel setting needs to consider that any responses observed may simply be reflecting a taxane-sensitive population. In this study, 42 patients had progressed either while receiving or within 6 weeks after completing docetaxel and 40% of them experienced a PSA decline of ‡50% with patupilone. These patients would generally be considered docetaxel resistant or refractory and thus suggests non-crossresistance.
Other epothilones have been tested in patients with CRPC, but single-agent results have not been as encouraging. Ixabepilone is a semisynthetic analog of epothilone B. In chemotherapy-naive patients with CRPC, a phase II study with ixabepilone was associated with grade 3-4 adverse events occurring in 45% of patients, consisting predominantly of neutropenia or leucopenia and neuropathy, and PSA responses (decline ‡50%) were observed to occur in 33% of patients [13] . A subsequent randomized phase II study evaluated ixabepilone or mitoxantrone/prednisone as secondline chemotherapy for CRPC in patients that progressed during or within 60 days of cessation of taxane chemotherapy [14] . PSA declines of ‡50% were observed in 17% of ixabepilone and 20% of mitoxantrone-treated patients. The most common grade 3/4 toxicity associated with second-line treatment was neutropenia (54% of ixabepilone patients and 63% of mitoxantrone patients). Another epothilone B analog, sagopilone, was evaluated in chemotherapy-naive CRPC patients in a phase II study [15] . Toxicity ‡grade 3 included neuropathy in 24% of patients and 21% experienced a PSA decline of ‡50%. KOS-862 (epothilone D) was tested as second-line chemotherapy in CRPC [16] . Only 2 patients (5.3%) met criteria for confirmed PSA decline and none of the 24 patients with measurable disease had a confirmed partial response. Treatment was not well tolerated with 73% of patients requiring dose delay, reduction, or treatment discontinuation from adverse events predominantly from neurological toxicity and fatigue.
The treatment of CRPC patients with chemotherapy continues to evolve and recently, cabazitaxel, a taxane, has been approved for use in patients previously treated with docetaxel based on overall survival benefits over mitoxantrone with a median improvement in survival of 2.4 months (hazard ratio = 0.70, P < 0.0001). With cabazitaxel, 39% of patients experienced a PSA decline of ‡50%, with a median PFS of 2.8 months, although the reported pain response rate was <10%, 82% of patients developed grade 3 or higher neutropenia with 8% experiencing febrile neutropenia and 5% of patients died within 30 days of last dose [17] . The results with cabazitaxel confirm the benefits of a strategy using new 
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tubulin-targeting agents in the postdocetaxel setting but also further demonstrate the challenges of treatment-related toxicity when treating this patient population with chemotherapy.
The therapeutic results obtained with patupilone compare favorably with other chemotherapy agents that have been tested in patients progressing after docetaxel. Based on the results of this study, additional clinical testing with patupilone in CRPC is warranted to further define palliative and survival benefits in patients progressing after docetaxel and/or cabazitaxel. 
